Assessing Medtronic (MDT) Valuation After Affera Deal And Cardiac Ablation Growth Outlook

Simply Wall St.02-01 09:36

Medtronic (MDT) is back in focus after recent analyst coverage spotlighted its Affera acquisition and the Cardiac Ablation Solutions segment, where the company projects an extra US$1b in sales by 2027...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608227006?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/31348-main-header/1756253047734","is_english":true,"pubTime":"2026-02-01 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608227006","market":"hk","top_or_hot":-1,"title":"Assessing Medtronic (MDT) Valuation After Affera Deal And Cardiac Ablation Growth Outlook","media":"Simply Wall St.","content":"<div>\n<p>Medtronic (MDT) is back in focus after recent analyst coverage spotlighted its Affera acquisition and the Cardiac Ablation Solutions segment, where the company projects an extra US$1b in sales by 2027...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/assessing-medtronic-mdt-valuation-after-affera-deal-and-card\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Medtronic (MDT) Valuation After Affera Deal And Cardiac Ablation Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Medtronic (MDT) Valuation After Affera Deal And Cardiac Ablation Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/assessing-medtronic-mdt-valuation-after-affera-deal-and-card><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medtronic (MDT) is back in focus after recent analyst coverage spotlighted its Affera acquisition and the Cardiac Ablation Solutions segment, where the company projects an extra US$1b in sales by 2027...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/assessing-medtronic-mdt-valuation-after-affera-deal-and-card\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1983299246.USD","symbol_name":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/assessing-medtronic-mdt-valuation-after-affera-deal-and-card","article_id":"2608227006","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/31348-main-header/1756253047734"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/assessing-medtronic-mdt-valuation-after-affera-deal-and-card","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608227006","pubTimestamp":1769909789,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medtronic (MDT) is back in focus after recent analyst coverage spotlighted its Affera acquisition and the Cardiac Ablation Solutions segment, where the company projects an extra US$1b in sales by 2027.\nSee our latest analysis for Medtronic.\nMedtronic’s recent Affera headlines come as the share price trades at US$102.96, with a 30 day share price return of 7.18% and a 90 day share price return of 13.52%. The 1 year total shareholder return of 16.94% suggests momentum has been building over the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4082":"医疗保健设备","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","MDT":"美敦力","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","CAS":"SIMPLIFY CHINA A SHARES PLUS INCOME ETF","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4566":"资本集团","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC"},"translate_title":"评估Affera交易后美敦力(MDT)的估值和心脏消融增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAS":1,"MDT":1.5},"content_text":"Medtronic (MDT) is back in focus after recent analyst coverage spotlighted its Affera acquisition and the Cardiac Ablation Solutions segment, where the company projects an extra US$1b in sales by 2027. See our latest analysis for Medtronic. Medtronic’s recent Affera headlines come as the share price trades at US$102.96, with a 30 day share price return of 7.18% and a 90 day share price return of 13.52%. The 1 year total shareholder return of 16.94% suggests momentum has been building over the past year. If this kind of steady interest in medical technology appeals to you, it could be a good moment to scan other opportunities across healthcare stocks. With Medtronic trading at US$102.96 and sitting close to analyst targets, the key question for you is simple: are you looking at an undervalued medical device leader, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 7.1% Undervalued Against Medtronic’s last close of $102.96, the most followed narrative points to a fair value of about $110.87, suggesting some valuation headroom based on its cash flow potential and long term earnings profile, using a discount rate of 8.73%.  The rapid global growth in chronic diseases (e.g., cardiovascular disease, diabetes) is driving sustained demand for Medtronic's advanced device offerings, as evidenced by strong momentum in Cardiac Ablation Solutions (CAS), innovative diabetes systems (Simplera Sync, Instinct), and new launches in hypertension management (Symplicity). This structural demand should accelerate revenue growth across core franchises.  Read the complete narrative. Curious what sits behind that fair value gap? This narrative leans on steadier revenue build, firmer margins, and an earnings profile that assumes disciplined execution without stretching the numbers. Result: Fair Value of $110.87 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Medtronic turning around underperforming areas like U.S. Diabetes and avoiding execution hiccups in launches such as Hugo and new CAS platforms. Find out about the key risks to this Medtronic narrative.  Build Your Own Medtronic Narrative If you see the numbers differently or prefer to test your own assumptions, you can build a personalised Medtronic view in just a few minutes, starting with Do it your way. A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If Medtronic is on your radar, do not stop there. Broaden your watchlist with a few focused screens that surface very different types of opportunities.  Target potential income by reviewing these 14 dividend stocks with yields > 3% that might suit a portfolio anchored around regular cash returns. Hunt for growth stories by scanning these 24 AI penny stocks where companies are tied to AI themes across different parts of the market. Spot possible mispricings by checking these 871 undervalued stocks based on cash flows that currently trade at a discount to their cash flow potential.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608227006","isCrawlerRequest":true}